Cash is always an issue for any emerging company. I'm confident that with the next round of money from the government that we will get through to interim trial results of xanaCIDD. Those results, if successful, will push the sp up significantly and also awaken one or two big pharmas. If the results are mediocre then we wait for xanaMia results in 2025. I remain bullish.
IMHO & DYOR
Ann: ACW December 2023 quarterly activity report & Appendix 4C, page-5
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.7¢ |
Change
0.001(3.85%) |
Mkt cap ! $79.51M | |||
| Open | High | Low | Value | Volume |
| 2.7¢ | 2.8¢ | 2.7¢ | $224.5K | 8.316M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 2785949 | 2.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.7¢ | 2741224 | 4 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| ACW (ASX) Chart |